open access

Vol 11, No 3 (2010): Practical Diabetology
Original articles (submitted)
Published online: 2010-11-05
Get Citation

Influence of selected inflammatory markers on occurrence and duration of partial remission in patients with type 1 diabetes

Paweł Niedźwiecki, Stanisław Piłaciński, Aleksandra Uruska, Paweł Uruski, Dorota Zozulińska-Ziółkiewicz, Bogna Wierusz-Wysocka
Diabetologia Praktyczna 2010;11(3):94-100.

open access

Vol 11, No 3 (2010): Practical Diabetology
Original articles (submitted)
Published online: 2010-11-05

Abstract


INTRODUCTION. Aim of the study was to asses the influence of selected inflammatory markers on occurrence and duration of remission in type 1 diabetes.
MATERIAL AND METHODS. 224 patients with newly diagnosed type 1 diabetes were qualified to the study. Partial remission was defined as HbA1c below 7% and daily exogenous insulin requirement below 0.5 U/kg and positive C-peptide level. The occurrence and duration of remission was assessed during regular visits in out-patient clinic. We divided patients according to occurrence of remission and its duration (above and below 1 year). The following inflammatory markers were taken into account: white blood cell count (WBC), serum C-reactive protein concentration (CRP), erythrocyte sedimentation rate (ESR), and concentration of serum myeloperoxidase (MPO).
RESULTS. 175 patients achieved partial remission. When compared with patients who did not experience remission remittents showed lower WBC (6.2 ± ± 1.4 v. 7.1 ± 2.7 103/ul; p < 0.03) and ESR (5.1 ± ± 3.3 v. 8.3 ± 12.2 mm/h; p < 0.02). Patients with shorter duration of remission had higher serum MPO level (250.6 ± 139.5 v. 163.9 ± 82.7 ng/ml; p = 0.008). Using logistic regression, significant association between serum MPO level (OR = 0.34, 95% CI: 0.12– –0.94; p < 0.03) and duration of remission was found.
CONCLUSIONS. The results of this study show that inflammatory process influences occurrence and duration of remission in patients with type 1 diabetes. MPO seems to be a prognostic marker of duration of remission. The higher serum concentration of the MPO, the shorter duration of remission in patients with type 1 diabetes. (Diabet. Prakt. 2010; 11, 3: 94–100)

Abstract


INTRODUCTION. Aim of the study was to asses the influence of selected inflammatory markers on occurrence and duration of remission in type 1 diabetes.
MATERIAL AND METHODS. 224 patients with newly diagnosed type 1 diabetes were qualified to the study. Partial remission was defined as HbA1c below 7% and daily exogenous insulin requirement below 0.5 U/kg and positive C-peptide level. The occurrence and duration of remission was assessed during regular visits in out-patient clinic. We divided patients according to occurrence of remission and its duration (above and below 1 year). The following inflammatory markers were taken into account: white blood cell count (WBC), serum C-reactive protein concentration (CRP), erythrocyte sedimentation rate (ESR), and concentration of serum myeloperoxidase (MPO).
RESULTS. 175 patients achieved partial remission. When compared with patients who did not experience remission remittents showed lower WBC (6.2 ± ± 1.4 v. 7.1 ± 2.7 103/ul; p < 0.03) and ESR (5.1 ± ± 3.3 v. 8.3 ± 12.2 mm/h; p < 0.02). Patients with shorter duration of remission had higher serum MPO level (250.6 ± 139.5 v. 163.9 ± 82.7 ng/ml; p = 0.008). Using logistic regression, significant association between serum MPO level (OR = 0.34, 95% CI: 0.12– –0.94; p < 0.03) and duration of remission was found.
CONCLUSIONS. The results of this study show that inflammatory process influences occurrence and duration of remission in patients with type 1 diabetes. MPO seems to be a prognostic marker of duration of remission. The higher serum concentration of the MPO, the shorter duration of remission in patients with type 1 diabetes. (Diabet. Prakt. 2010; 11, 3: 94–100)
Get Citation

Keywords

myeloperoxidase; inflammation; remission; diabetes

About this article
Title

Influence of selected inflammatory markers on occurrence and duration of partial remission in patients with type 1 diabetes

Journal

Clinical Diabetology

Issue

Vol 11, No 3 (2010): Practical Diabetology

Pages

94-100

Published online

2010-11-05

Bibliographic record

Diabetologia Praktyczna 2010;11(3):94-100.

Keywords

myeloperoxidase
inflammation
remission
diabetes

Authors

Paweł Niedźwiecki
Stanisław Piłaciński
Aleksandra Uruska
Paweł Uruski
Dorota Zozulińska-Ziółkiewicz
Bogna Wierusz-Wysocka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl